-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $30

Benzinga·11/10/2026 12:57:43
Listen to the news
Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $54 to $30.